Author:
Ficker D. M.,Privitera M.,Krauss G.,Kanner A.,Moore J. L.,Glauser T.
Abstract
The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients’ adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献